Clinical Trial Update: Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of an EGFR-TKI combined with nimotuzumab for leptomeningeal metastases in lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Hui Bu | Conditions: Leptomeningeal Metastasis, Lung Cancer | Phase 2 | Status: UNKNOWN